Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
US-9193790-B2 · Nov 24, 2015 · US
Antibodies to integrin avb6 and use of same to treat cancer
US2016376368A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016376368-A1 |
| Application number | US-201615258699-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 7, 2016 |
| Priority date | Feb 17, 2012 |
| Publication date | Dec 29, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides antibodies that specifically bind to integrin ανβ6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ανβ6.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating a patient having cancer, comprising administering to the patient an effective regime of an antibody that specifically binds integrin ανβ6, wherein the antibody comprises heavy chain complementary determining region (CDR) sequences as set forth in SEQ ID NO:3 (CDR1), SEQ ID NO:4 (CDR2), and SEQ ID NO:5 (CDR3), and light chain CDR sequences as set forth in SEQ ID NO:6 (CDR4), SEQ ID NO:7 (CDR5), and SEQ ID NO:8 (CDR6) and having 0, 1, 2 or 3 conservative amino acid substitutions in each CDR.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title
Complementarity determining region [CDR] · CPC title
- C07K16/2839Primary
against the integrin superfamily · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016376368A1 cover?
- The invention provides antibodies that specifically bind to integrin ανβ6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ανβ6.
- Who is the assignee on this patent?
- Seattle Genetics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2839. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Dec 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).